AOAC validates Merck tests to detect Salmonella in peanut butter products

07-Jul-2009 - Merck announced that the AOAC Research Institute has validated two of its products for the detection of Salmonella in peanut butter products within the scope of its Emergency Response Validation (ERV) program. Effective immediately, food manufacturers and inspectors can use both the foodproof® ...

Tracleer (bosentan) receives EU approval for pediatric formulation

The first and only licensed pulmonary arterial hypertension therapy for children

07-Jul-2009 - Actelion Ltd announced that the pediatric dispersible formulation of Tracleer® (bosentan) for the treatment of pulmonary arterial hypertension (PAH) in children has been approved in the European Union. This approval makes Tracleer® the only PAH therapy with an approved pediatric formulation for ...

Novartis delivers 250,000,000th Coartem treatment

Novartis becomes first healthcare company to join United Against Malaria partnership

07-Jul-2009 - Novartis announced the delivery of the 250,000,000th treatment of Coartem, a artemisinin-based combination therapy (ACT) for the treatment of malaria. To mark this occasion, Dr. Daniel Vasella, Chairman and CEO of Novartis, delivered the milestone dose to Mwananyamala District Hospital in Dar es ...

BioInvent and ThromboGenics Start Recruitment of Second 100 Patient Cohort in Phase II DVT Prophylaxis Study with TB-402

06-Jul-2009 - BioInvent International AB and ThromboGenics NV announce that they have started recruitment of a second cohort of patients for their Phase II trial of TB-402. This follows completion of recruitment of the first cohort of 100 patients ahead of schedule. TB-402 is a novel, long acting anticoagulant ...

Clavis Pharma announces successful Investigational New Drug application (IND) review for Intravenous CP-4126

06-Jul-2009 - Clavis Pharma ASA announces that it has received clearance by the United States Food and Drug Administration (FDA) to include patients in the USA in its phase II clinical programme for Intravenous CP-4126. Intravenous CP-4126 is in development as a new, first-line treatment for pancreatic cancer ...

GENEART Again Honored with "BAVARIA'S BEST 50" Award

GENEART is among the 50 most dynamic companies in Bavaria

03-Jul-2009 - GENEART AG is among the 50 most dynamic companies in Bavaria and has been awarded "BAVARIA'S BEST 50" by the Bavarian State Ministry for the third time. Since its market entry in 2000, GENEART evolved to the world market leader in synthetic gene production, according to the company. Furthermore, ...

Lu AA24530 shows positive results in major depressive disorder phase II study

03-Jul-2009 - H. Lundbeck A/S announced positive headline results from a dose finding clinical trial with the compound Lu AA24530 for the treatment of major depressive disorder (MDD). The primary objective of the study was to compare the efficacy of three doses of Lu AA24530, 5, 10 and 20 mg, to that of ...

IOP announces 2009 award winners

03-Jul-2009 - Successful business applications such as drug screening technologies, flat-panel displays and solar-cell designs are amongst the achievements in physics recognised by the Institute of Physics' (IOP) 2009 awards along with leading research in a wide range of fields from astronomy to optical ...

Comprehensive and User-Friendly Biotech News, Constantly Updated

Bionity.COM expands its daily news coverage

03-Jul-2009 - BionityCOM, an online information portal provided by Chemie.DE Information Service GmbH, now offers the most comprehensive coverage of news for the biotech and pharma industries in Europe. Bionity.COM's specialist editorial team repeatedly updates the access-free industry news section during the ...

Pharming confirms positive results from final analysis of Rhucin studies

02-Jul-2009 - Pharming Group NV announced that, as part of the activities for the regulatory submission files, it has now also completed the final analysis of its Rhucin® randomised placebo-controlled studies. The results confirm the positive and consistent efficacy and safety of Rhucin in the treatment of ...